Effect of Testosterone Treatment on Constitutional and Sexual Symptoms in Men With Type 2 Diabetes in a Randomized, Placebo-Controlled Clinical Trial

• Published in: The journal of clinical endocrinology and metabolism 2014-10, Vol.99 (10), p.3821-3828
• Main Authors: Gianatti, Emily J, Dupuis, Philippe, Hoermann, Rudolf, Zajac, Jeffrey D, Grossmann, Mathis
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aging; Androgens - administration & dosage; Androgens - adverse effects; Androgens - blood; Depression - complications; Diabetes Mellitus, Type 2 - complications; Double-Blind Method; Erectile Dysfunction - drug therapy; Erectile Dysfunction - etiology; Hormone Replacement Therapy - adverse effects; Hormone Replacement Therapy - methods; Humans; Libido - drug effects; Male; Middle Aged; Obesity - complications; Placebos; Testosterone - administration & dosage; Testosterone - adverse effects; Testosterone - analogs & derivatives; Testosterone - blood; Treatment Outcome
• ISSN: 0021-972X; 1945-7197
• DOI: 10.1210/jc.2014-1872

Objective: The objective of the study was to assess the effect of T treatment on constitutional and sexual symptoms in men with type 2 diabetes (T2D). Design: This was a randomized double-blind, parallel, placebo-controlled trial. Setting: The study was conducted at a tertiary referral center. Patients: Men aged 35–70 years with T2D, a hemoglobin A1c less than 8.5%, and a total T level less than 12.0 nmol/L (346 ng/dL) with mild to moderate aging male symptoms and erectile dysfunction. Intervention: Eighty-eight participants were randomly assigned to 40 weeks of im T undecanoate (n = 45) or matching placebo (n = 43). Main Outcome Measures: Constitutional symptoms using the aging male symptoms (AMS) score, sexual desire (question 17 AMS score), and erectile function (International Index of Erectile Function-5). Results: T treatment did not substantially improve aging male symptoms [mean adjusted difference (MAD) in change over 40 weeks across the T and placebo groups in AMS total score, −0.9 (95% confidence interval [CI] −4.1, 2.2), P = .67] or sexual desire [MAD in question 17 AMS, −0.3 (95% CI −0.8, 0.2), P = .17]. Although compared with placebo, erectile function in men assigned to T was reduced [MAD in International Index of Erectile Function abridged version 5, −2.0 (95% CI −3.4, −0.6), P < .02], there was no significant difference between baseline and 40-week International Index of Erectile Function abridged version 5 scores if both groups were analyzed separately. At baseline, symptoms were worse in men with depression and microvascular complications but did not correlate with T levels. Conclusions: In this trial, T treatment did not substantially improve constitutional or sexual symptoms in obese, aging men with T2D with mild to moderate symptoms and modest reduction in T levels typical for the vast majority of such men.